Related Experiment Videos
[Management for 145 cases of Merkel cell carcinoma]
1Centre hospitalier universitaire d'Amiens, France. avi.assouline@psl.aphp.fr
Bulletin Du Cancer
|August 5, 2010
Summary
Treatment of relapsed Merkel cell carcinoma (MCC), a rare cancer, benefits from a multidisciplinary approach. Further multicenter trials are needed to confirm the best strategy for this aggressive malignancy.
Area of Science:
- Oncology
- Dermatology
Context:
- Merkel cell carcinoma (MCC), also known as primary cutaneous neuroendocrine carcinoma, is a rare and aggressive skin cancer.
- Optimal therapeutic strategies for MCC, particularly in cases of relapse, remain to be fully established.
Purpose:
- To analyze the management and outcomes of 145 patients with Merkel cell carcinoma across five centers.
- To evaluate the effectiveness of salvage therapy in patients with relapsed MCC.
- To identify the need for further research into optimal treatment strategies.
Summary:
- A retrospective analysis of 145 MCC patients revealed a median age of 78 years.
- Relapse patterns included 37 local, 37 regional, and 15 distant recurrences.
- Salvage therapy was considered for patients with acceptable health status upon relapse.
Impact:
- The study suggests that a multidisciplinary approach is beneficial for managing relapsed MCC.
- Findings highlight the necessity for multicenter prospective trials to validate optimal treatment protocols for Merkel cell carcinoma.
- This research contributes to understanding the challenges and potential solutions in treating this rare and aggressive cancer.
